The
main objective of promoting this new diagnostic marketing and
services company in India is to directly promote to the end-user
customers the advanced molecular diagnostic technologies and related
research products that provide a quality of clinical relevance in the
Indian subcontinent.
This sector is dominated by the Indian trading companies, which
represents technical inadequacies or moderate capability and tendency
to build up heavy selling costs. This tends to disable the very cause
of clinical applications of the advanced molecular tests. By bridging
a link with end-user customers the company ensures not only quality
products at affordable prices but also conducive personalized services
necessary in diagnostic/ clinical research industry.
The current core area being DIGENE’s US FDA approved Hybrid Capture 2
HPV DNA test for early diagnosis, management and prevention of
Cervical Cancer afflicting women in their most reproductive age group
and constituting a major cause of death due to any cancers among
women. Also marketed are the US FDA approved Chlamydia DNA,
Gonorrhoeae DNA technologies in the STD area and Cytomegalovirus DNA
technology in immunocompromised and organ transplant area. The other
core area pursued by the company is Hepatitis B, the product profile
is represented by DIGENE’s HBV DNA Hybrid Capture 2 and GENERAL
BIOLOGICAL CORPORATION, Taiwan’s HBV genotype on real time PCR
technology in therapeutic monitoring of chronically infected liver
patients. Soon, the molecular tests for HCV RNA quantitative and
genotyping as well as HIV-1 RNA tests are scheduled for launch.
The Company pursues active interest in promoting MOLECULAR BIOLOGY
DIAGNOSTICS and SPECIALTY IMMUNODIAGNOSTICS in the area of HIV/ AIDS,
HEPATITIS, CANCER and AUTOIMMUNE Markers and other tropical diseases
diagnostics such as MALARIA, TUBERCULOSIS, DENGUE, SALMONELLA etc.
TYPES OF SERVICES:
Gentech’s commitment to the elite gynaecology and hepatology
specialists in our core area of operation is to provide the quality of
Digene tests at extremely competitive and affordable prices. Our
commitment is emulated in TWO unique ways establishing synergistic
approach in the ever-more-demanding health care market.
1. Direct Marketing of the molecular diagnostics & research
products, and
2. Laboratory Testing services to our core clinical experts.
To reinforce our faith in direct-to-customer, the Company has also
promoted a NATIONAL CLINICAL REFERENCE LABORATORY, which is a support
service in cohesion with top echelon pathology laboratories in India
to commercially promote tests to the Indian Gynaecologists,
Hepatologists and Oncologists at the very competitive prices making a
modern technology in this “genomic era” more affordable to those who
are less fortunate. This laboratory is also designed to routinely
train the laboratory technologists from India and neighboring
countries including Bangladesh and UAE. The laboratory services also
extend to running clinical trials for the therapeutic manufacturers to
monitor the patients at the periodic intervals on the efficacy of the
long-term therapeutic effects. We have already finished two clinical
trials and a third, with a leading multinational is on for last two
years.
The NATIONAL CLINICAL REFERENCE LABORATORY is set up with the
commissioning of Digene’s modern proprietary Hybrid Capture system
consisting of chemiluminescence based 96-well Plate Luminometer, Tube
Luminometer, Rotary Shaker, Heating Block and automated micropipetting
system. The facility launched in May 2001 performs tests on weekly
intervals. The laboratory holds some of the world reputed
Gynaecologists and Hepatologists in India on advisory and consulting
panel, to substantiate our commitment to Indian diagnostic industry.
The Company also plans to create a networking of Referral Laboratories
in the major cities in India through franchisee system involving
financial participation from the leading pathological laboratories.
ORGANISATIONAL CULTURE:
The Company believes strongly in minimal but technically competent
and committed manpower to deal with the class of our target markets.
It is important that they carry out effectively the product
presentations, follow-up potentials and convert them into long-term
deals, provide technology training, concentrate trouble-shoot through
individual attention and care within shortest possible time, support
with most appropriate clinical interpretations of the technologies
being marketed and finally gain “friendship access” to elite
customers. With the benefits of Information Technology era, it is
possible to be constantly in-touch with the large number customers
simultaneously. This is how we see developing long-lasting
relationship with them. Our marketing collaborating company provides a
constant supplement of technical resource and support which is
drafted, edited or summarized, if the need be, in the manner easily
understood in our target markets. We are largely acknowledged and
appreciated in our novel endeavor in Indian diagnostic industry.
HPV Resource Information on the Internet :
|
